1. Home
  2. LIXT vs NUWE Comparison

LIXT vs NUWE Comparison

Compare LIXT & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • NUWE
  • Stock Information
  • Founded
  • LIXT 2005
  • NUWE 1999
  • Country
  • LIXT United States
  • NUWE United States
  • Employees
  • LIXT N/A
  • NUWE N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • LIXT Health Care
  • NUWE Health Care
  • Exchange
  • LIXT Nasdaq
  • NUWE Nasdaq
  • Market Cap
  • LIXT 4.1M
  • NUWE 3.9M
  • IPO Year
  • LIXT N/A
  • NUWE N/A
  • Fundamental
  • Price
  • LIXT $1.33
  • NUWE $0.40
  • Analyst Decision
  • LIXT
  • NUWE Strong Buy
  • Analyst Count
  • LIXT 0
  • NUWE 1
  • Target Price
  • LIXT N/A
  • NUWE $17.00
  • AVG Volume (30 Days)
  • LIXT 22.1K
  • NUWE 187.8K
  • Earning Date
  • LIXT 05-12-2025
  • NUWE 05-13-2025
  • Dividend Yield
  • LIXT N/A
  • NUWE N/A
  • EPS Growth
  • LIXT N/A
  • NUWE N/A
  • EPS
  • LIXT N/A
  • NUWE N/A
  • Revenue
  • LIXT N/A
  • NUWE $8,787,000.00
  • Revenue This Year
  • LIXT N/A
  • NUWE $26.81
  • Revenue Next Year
  • LIXT N/A
  • NUWE $48.74
  • P/E Ratio
  • LIXT N/A
  • NUWE N/A
  • Revenue Growth
  • LIXT N/A
  • NUWE N/A
  • 52 Week Low
  • LIXT $1.02
  • NUWE $0.40
  • 52 Week High
  • LIXT $3.50
  • NUWE $8.40
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 50.90
  • NUWE 15.96
  • Support Level
  • LIXT $1.16
  • NUWE $0.76
  • Resistance Level
  • LIXT $1.49
  • NUWE $0.95
  • Average True Range (ATR)
  • LIXT 0.11
  • NUWE 0.09
  • MACD
  • LIXT 0.00
  • NUWE -0.05
  • Stochastic Oscillator
  • LIXT 51.45
  • NUWE 0.00

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About NUWE Nuwellis Inc.

Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Share on Social Networks: